A Stability Indicating UPLC Method for Candesartan in Bulk Drug Samples

Gunda Srinivas, Kakumani Kishore Kumar, Gangaram V. Kanumula, M. Vishnu Priya, K. Mukkanti

Centre for Chemical Sciences and Technology, Institute of Sciences and Technology.
Centre for Chemical Sciences and Technology, Institute of Sciences and Technology, Jawaharlal Nehru Technological University, Hyderabad, India.
CTO-2, Dr. Reddy’s Laboratories Ltd., Hyderabad, India.

DOI: 10.4236/ajac.2012.310093                

Abstract

A simple, sensitive gradient rapid resolution liquid chromatographic assay method has been developed for the quantitative determination of Candesartan Cilexetil in bulk active pharmaceutical ingredient, used for the treatment of hypertension. The developed method is also applicable for the process related impurities determination. Efficient chromatographic separation was achieved on a C18 stationary phase with simple mobile phase combination delivered in a gradient mode and quantification was by ultraviolet detection at 210 nm at a flow rate of 0.4 mL × min^﹣1. In the developed UPLC method the resolution between Candesartan Cilexetil and its two potential impurities was found to be greater than 2.0. Regression analysis showed an r value (correlation coefficient) greater than 0.99 for Candesartan Cilexetil and its two impurities. This method was capable to detect two impurities of Candesartan Cilexetil at a level of 0.003% with respect to test concentration of 1.0 mg × mL^﹣1 for a 2 μL injection volume. The bulk active pharmaceutical ingredient was subjected to stress conditions of hydrolysis, oxidation, photolysis and thermal degradation. Considerable degradation was found to occur in oxidative stress conditions. The stress samples were assayed against a qualified reference standard and the mass balance was found close to 99.5%. The developed RP-LC method was validated with respect to linearity, accuracy, precision and robustness.

Keywords

Column Chromatography; Forced Degradation; Stress Conditions; Candesartan Cilexetil

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	E. Nevin, “Simultaneous Analysis of Candesartan Cilexetil and Hydrochlorothiazide in Human Plasma and Dosage Forms Using HPLC with a Photodiode Array Detector,” Journal of Liquid Chromatography & Related Technologies, Vol. 26, No. 15, 2003, pp. 2581-2591. doi:10.1081/JLC-120023802
[2]	C. Fenton and L. J. Scott, “A Review of Its Use in the Management of Chronic Heart Failure,” Drugs, Vol. 65, No. 4, 2005, pp. 537-558. doi:10.2165/00003495-200565040-00007
[3]	R. Revathi, T. Ethiraj, J. L. Marreddy and V. Ganeshan, “Development and Validation of a Dissolution Test for Candesartan Cilexetil in Tablet Forms Using Reverse Phase—High Performance Liquid Chromatography,” Journal of Pharmaceutical Education and Research, Vol. 2, No. 2, 2011, pp. 71-77.
[4]	M. M. Annapurnaa, A. Narendra and K. R. Kumar, “Liquid Chrmotographic Method for Determination of Candesartan Cilexetil and Hydrochlorothiazide in Pharmaceutical Dosage Forms,” Journal of Drug Delivery & Therapeutics, Vol. 2, No. 2, 2012, pp. 48-54.
[5]	K. B. Tejaswini, K. M. Shrinivas and S. M. Chandrakant, “Simultaneous Estimation of Candesartan Cilexetil and Hydrochlorothiazide in Tablet Dosage Form by UV Spectrophotometric Method,” International Journal of Pharm-tech Research, Vol. 4, No. 2, 2012, pp. 786-790.
[6]	S. T. Prajapati, P. K. Patel, M. Patel, V. B. Chauhan, and C. N. Patel, “Development and Validation of the Liquid Chromatography-Tandem Mass Spectrometry Method for Quantitative Estimation of Candesartan from Human Plasma,” Pharmaceu-tical Methods, Vol. 2, No. 2, 2011, pp. 130-134.
[7]	B. H. Mehta and S. B. Morge, “HPTLC-Densitometric Analysis of Candesartan Cilexetil and Hydrochlorothiazide in Tablets,” Journal of Planar Chromatography, Modern TLC, Vol. 21, No. 2, 2008, pp. 173-176. doi:10.1556/jpc.21.2008.3.3
[8]	Y. D. Zhang, X. H. Wei, A. F. Wang, Y. J. Xu, X. H. Zhu and J. M. Luo, “HPLC Determination of Candesartan Cilexetil and Its Related Substances,” Central South Pharmacy, Vol. 2, No. 2, 2004, pp. 80-83.
[9]	N. Devanaboyina and T. Satyanarayana, “Simultaneous Determination of Candesartan and Hydrochlorothiazide in Combined Pharmaceutical Dosage Form by New RP- HPLC Method,” Research Journal of Pharmaceutical, Biological and Chemical, Sciences, Vol. 3, No. 1, 2012, pp. 270-278.